Sirius Medical is proud to announce the first clinical results and global commercial implants of the Sirius Pintuition system.
The first clinical safety and performance study shows that Sirius Pintuition System is safe and performs as intended for breast cancer patients. The results will be presented at the European Society of Surgical Oncology virtual conference on October 23. The study was led by M.D. Maud Bessems, surgical oncologist and principal investigator at the Jeroen Bosch Breast Centre (JBZ) in ‘s Hertogenbosch, the Netherlands.
The first global commercial implants of the Sirius Pintuition system took place in the Elisabeth-TweeSteden (ETZ) hospital in Tilburg, the Netherlands. The ETZ is one of 26 top clinics in the Netherlands. It has 4,000 full-time employees and is one of the largest non-academic training hospitals in the Netherlands.